- Apr 17, 2023
- Healthcare Providers Rank Fujifilm “Best in KLAS” in Latin America for Two Synapse® Enterprise Imaging Solutions
- Sep 30, 2021
- Fujifilm agrees on core terms with Australian regenerative medicine venture Cynata to manufacture Cynata’s iPS cell-derived regenerative medicine products
- Sep 27, 2021
- Fujifilm’s portable X-ray system “FDR Xair System” obtains recommendation from the Stop TB Partnership as an X-ray device for tuberculosis screening
- Sep 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Aug 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera®
- Jun 23, 2021
- Marketing Authorization Granted for Lutathera® Injection in Japan
- Mar 30, 2021
- FUJIFILM Healthcare starts to operate as Fujifilm Group company
- Mar 30, 2021
- Fujifilm launches “FUJIFILM COVID-19 Ag Test”, a SARS-CoV-2 antigen rapid diagnostic test with a highly-sensitive detection technology based on silver halide amplification, in Europe
- Mar 19, 2021
- Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America
- Feb 18, 2021
- Notice Concerning the Completion Timing for the Acquisition of Hitachi’s Diagnostic Imaging-related Business
- Jan 29, 2021
- Transfer of Shares in Japan Tissue Engineering Co., Ltd. to TEIJIN LIMITED
- Jan 7, 2021
- Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
- Jan 5, 2021
- Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility